Burden of respiratory syncytial virus infection in young children.

By B. Resch. World Journal of Clinical Pediatrics, 2012

1,197 citations recorded by the source corpus.

Respiratory syncytial virus (RSV) is the most frequent and important cause of lower respiratory tract infection in infants and children. It is a seasonal virus, with peak rates of infection occurring annually in the cold season in temperate climates, and in the rainy season, as temperatures fall, in tropical climates. High risk groups for severe RSV disease include infants below six mo of age, premature infants with or without chronic lung disease, infants with hemodynamically significant congenital heart disease, infants with immunodeficiency or cystic fibrosis, and infants with neuromuscular diseases. Mortality rates associated with RSV infection are generally low in previous healthy infants (below 1%), but increase significantly in children with underlying chronic conditions and comorbidities. Following early RSV lower respiratory tract infection, some patients experience recurrent episodes of wheezing mimicking early childhood asthma with persistence of lung function abnormalities until adolescence. There is currently no RSV vaccine available, but promising candidate vaccines are in development. Palivizumab, a monoclonal RSV antibody that is the only tool for immunoprophylaxis in high-risk infants, lowers the burden of RSV infection in certain carefully selected patient groups.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/fbead49ffe46b3cef74d3d9eae7b619891b18294

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Pulmonary and Respiratory Medicine

In Surgery

Citations in the corpus

Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine (2016, positive): “Human respiratory syncytial virus (RSV) infects virtually all children by two years of age and accounts for ~50% of hospitalizations due to respiratory infections in this age group 1-4 .”
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism (2015, neutral): “of reflections 32,193 (2,647) 36,384 (2,741) Rwork/Rfree (%) 17.”
The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (2011, background): “Respiratory syncytial virus is the most common viral etiology of hospitalization for CAP in infants [329].”
Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. (2012, methodology): “Using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), frozen specimens previously evaluated for influenza were tested for RSV using methods published by the Centers for Disease Control and Prevention (CDC) [31] and for HMPV using primers and probes modified from Maertzdorf et al ”
Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of Age (2013, neutral): “33 Public 300 (54) 884 (56) Private 216 (39) 555 (35) None 39 (7) 139 (9) Unknown 4 (1) 12 (1) Palivizumab 19 (3) 93 (6) .”
Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming (2009, background): “RSV is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age and is a serious health problem for elderly peopl”